NCT05672043Recruiting
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Perspective Study on Genetic Predispositions and Clinical Prognosis of Children and Adolescents With Malignant Brain Neoplasms in China
Source: ClinicalTrials.gov · Last updated 5 Jan 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 3 Jan 2023
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT05672043
What you commit to
- Study type: Observational
- Planned participants: 400
- From 1 Jan 2023 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with major systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) which might compromise the patient's ability to tolerate standard treatment or would likely interfere with overall prognosis;
Lab values
- Quality of tumor tissue sample did not meet the criterion for genetic sequencing and laboratory investigations;
Other
- \- Patients with major perioperative complications which lead to significant and sudden deterioration;
- Patients with major adverse events or sudden deterioration irrelevant to the current study;
- Patients who refuse to participate in the study or who request dropping out from the study
Who the study is looking for
- \- Children and adolescents aged between 0-18 years old, diagnosed with medulloblastoma or other malignant central nervous system tumors including glioma, ependymoma, germ cell tumors,tuberous sclerosis, neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid/rhabdoid tumors, ependymoblastoma, and medulloepithelioma;
- Patients must be eligible for and receive tumor resection;
- Histological examination by institutional neuro-pathological evaluation must confirmed the diagnosis of brain malignancies;
- Participants consent with joining the current study and comply with follow-up visits;
- The patients must have no previous radiotherapy or chemotherapy other than corticosteroids.
Age in the registry: 0 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hosiptal Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.